During brosis of the liver, a collagen-rich extracellular matrixa network of material that lls the space between cells -replaces healthy tissue, leading to the formation of scar tissue.
Fibrosis can progress to cirrhosis, in which scar tissue increasingly disrupts blood ow in the liver and compromises the organ's functions. This can lead to liver failure and even death.
People with cirrhosis have an elevated risk of developing liver cancer 1 -the leading cause of death in those with asymptomatic cirrhosis. Individuals with the viral liver infection hepatitis C, which leads to cirrhosis, have the highest risk: up to 30% of infected people in Japan will develop cancer in the ve years that follow diagnosis 1 . Treating the underlying disease reduces a person's risk, but it remains elevated 2 .
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Building blocks
Oxygenated blood enters the liver through the hepatic artery, and deoxygenated but nutrient-rich blood enters through the hepatic portal vein from the intestines. The incoming blood mixes in structures known as sinusoids, which are lined with endothelial cells and hepatocytes -cells that carry out most of the liver's functions. Blood then leaves the liver by the central vein. 
Fibrosis
ROAD TO FIBROSIS
EVIDENCE BUILDS
Liver brosis and cirrhosis were long thought to be irreversible. But over several decades, researchers have shown that brosis can be undone. The liver is now known to make and break down scar tissue continuously, which raises the possibility that drugs could be used to tip the balance in favour of healing.
3
Target hit
In a large trial, 87% of people treated for hepatitis B with an antiviral drug see an improvement in brosis after ve years 7 .
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Clinical hints
Numerous small clinical studies hint that brosis can improve after treatment for liver diseases. But the general view remains that brosis is irreversible.
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Key enzymes
Enzymes that degrade collagen in the extracellular matrix are found in rat models of liver brosis 3 , which suggests that the body is able to remove scar tissue.
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Rat reversal
A detailed study reveals that brosis can be reversed in rats through the increased activity of collagendigesting enzymes and the death of myo broblasts 4 . 
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Stop and start
Shoot the messenger
Drugs that prevent brosis-promoting signalling molecules, such as cytokines, from reaching HSCs are being investigated. Cenicriviroc, a small molecule that blocks two types of cytokine receptor, is now in phase III clinical trials. Small molecules that target other receptors, and antibodies that bind to secreted messengers, are also being explored.
Bring on fresh players
Clinical trials that introduce stem cells into the liver have failed to induce therapeutic e ects. But in the mouse liver, macrophages have been shown to produce strong anti brotic e ects 8 -phase I trials are under way.
Interfere with integrins
Integrins are cell-surface receptors that are activated by cell-extracellular matrix or cell-cell interactions. They can have multiple pro brotic e ects. Integrins α v β 1 and α v β 6 have emerged as especially exciting targets for the treatment of liver brosis, and numerous small molecules and antibodies that inhibit integrins are approaching phase I trials.
Remove myo broblasts
Drugs that block intracellular signalling pathways that maintain HSC activation, or mimic signals that promote the death of myo broblasts or their reversion to HSCs, are being sought to speed the resolution of brosis.
Destroy the matrix
Small interfering RNAs (siRNAs) that halt collagen synthesis by binding to collagenencoding messenger RNA are being pursued. An siRNA targeted to HSCs that suppresses a protein needed for collagen to mature has completed phase I trials. Drugs that block collagen cross-linking enzymes or inhibitors of enzymes that digest collagen might also aid scar breakdown.
The body's innate ability to undo liver brosis means that tackling the underlying cause -with antiviral drugs or by reducing alcohol intake, for instance -can help to resolve scarring. But there is also a need for drugs that directly target the brotic process to halt or even prevent scarring, and thereby lessen liver damage.
QUEST FOR TREATMENTS
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Challenges to overcome
Liver brosis tends to progress over decades. Clinical trials can therefore take years to complete and often require many participants. But researchers are searching for biomarkers in blood that indicate changes in the rates of scar formation and breakdown. These molecules could reveal within a matter of weeks whether potential drugs are working. 
